{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T15:51:34Z","timestamp":1792511494897,"version":"4.5.0"},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","license":[{"start":{"date-parts":[[2025,1,17]],"date-time":"2025-01-17T00:00:00Z","timestamp":1737072000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,1,17]]},"abstract":"<jats:sec>\n            <jats:title>Rationale:<\/jats:title>\n            <jats:p>Chylothorax is a rare adverse effect that is associated with dasatinib, a tyrosine kinase inhibitor administered for chronic myeloid leukemia (CML) treatment. Most reported cases have described standard dosing. In this case report, we described a 43-year-old male patient with CML who developed chylothorax after 4 years of low-dose dasatinib therapy. To the best of our understanding, this is the first case to report the simultaneous development of pulmonary hypertension, pericardial effusion, and dasatinib-induced chylothorax.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patient concerns:<\/jats:title>\n            <jats:p>A 43-year-old male patient with CML developed chylothorax after 4 years of low-dose dasatinib.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Diagnoses:<\/jats:title>\n            <jats:p>The patient also developed pulmonary hypertension and pericardial effusion at the same time.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Interventions:<\/jats:title>\n            <jats:p>Therapeutic interventions included thoracentesis, steroids, diuretics, and sildenafil. Dasatinib was discontinued and replaced with nilotinib, which resolved the chylothorax, pulmonary hypertension, and pericardial effusion.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Outcomes:<\/jats:title>\n            <jats:p>Chylothorax occurs with long-term and low-dose dasatinib administration. Concurrent pulmonary hypertension and pericardial effusion, although infrequent, may occur. Prompt recognition, dasatinib discontinuation, and therapeutic interventions are crucial for optimizing outcomes.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Lessons:<\/jats:title>\n            <jats:p>Close monitoring for these rare side effects is paramount even in patients on long-term or low-dose dasatinib.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000041328","type":"journal-article","created":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T03:03:30Z","timestamp":1737428610000},"page":"e41328","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":6,"title":["Low-dose dasatinib-induced chylothorax, pulmonary hypertension, and pericardial effusion in a patient with chronic myeloid leukemia: A case report and literature review"],"prefix":"10.1097","volume":"104","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-2209-0938","authenticated-orcid":false,"given":"Ting-Wei","family":"Pai","sequence":"first","affiliation":[{"name":"Department of Medical Education, Changhua Christian Hospital, Changhua, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3706-0480","authenticated-orcid":false,"given":"Cheng-Wei","family":"Huang","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Changhua Christian Hospital, Changhua, Taiwan."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250121","doi-asserted-by":"crossref","first-page":"100825","DOI":"10.1016\/j.blre.2021.100825","article-title":"Chronic myeloid leukemia: modern therapies, current challenges and future directions.","volume":"49","author":"Osman","year":"2021","journal-title":"Blood Rev"},{"key":"R2-20250121","doi-asserted-by":"crossref","first-page":"773","DOI":"10.2147\/DDDT.S80207","article-title":"The role of dasatinib in the management of chronic myeloid leukemia.","volume":"9","author":"Chen","year":"2015","journal-title":"Drug Des Devel Ther"},{"key":"R3-20250121","doi-asserted-by":"crossref","first-page":"2045894019865704","DOI":"10.1177\/2045894019865704","article-title":"Pulmonary hypertension with dasatinib and other tyrosine kinase inhibitors.","volume":"9","author":"El-Dabh","year":"2019","journal-title":"Pulm Circ"},{"key":"R4-20250121","doi-asserted-by":"crossref","first-page":"163","DOI":"10.3324\/haematol.2010.030494","article-title":"Extensive pleural and pericardial effusion in chronic myeloid leukemia during treatment with dasatinib at 100\u2009mg or 50\u2009mg daily.","volume":"96","author":"Krauth","year":"2011","journal-title":"Haematologica"},{"key":"R5-20250121","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1177\/14782715241237577","article-title":"Drug-induced chylothorax as a rare pleural complication in dasatinib therapy for chronic myeloid leukaemia.","volume":"54","author":"Ng","year":"2024","journal-title":"J R Coll Physicians Edinb"},{"key":"R6-20250121","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1007\/s10637-020-00932-3","article-title":"Dasatinib-induced chylothorax: report of a case and review of the literature.","volume":"38","author":"Chen","year":"2020","journal-title":"Invest New Drugs"},{"key":"R7-20250121","doi-asserted-by":"crossref","first-page":"68","DOI":"10.4274\/tjh.2012.0196","article-title":"Dasatinib-related chylothorax.","volume":"32","author":"Huang","year":"2015","journal-title":"Turk J Haematol"},{"key":"R8-20250121","first-page":"003601","article-title":"A dasatinib-induced chylothorax persisting after the discontinuation of dasatinib.","volume":"9","author":"Bradt","year":"2022","journal-title":"Eur J Case Rep Intern Med"},{"key":"R9-20250121","doi-asserted-by":"crossref","first-page":"3139","DOI":"10.2169\/internalmedicine.3002-19","article-title":"Successful control of dasatinib-related chylothorax by the Japanese herbal medicine \u201cGoreisan\u201d.","volume":"58","author":"Sasaki","year":"2019","journal-title":"Intern Med"},{"key":"R10-20250121","first-page":"003921","article-title":"Dasatinib-induced chylothorax beyond 5 years of treatment: is there actually any limit?","volume":"10","author":"Garcia-Zamalloa","year":"2023","journal-title":"Eur J Case Rep Intern Med"},{"key":"R11-20250121","first-page":"76","article-title":"Dasatinib-induced chylothorax: a clinical laboratory\u2019s perspective.","volume":"34","author":"Mart\u00ednez","year":"2023","journal-title":"EJIFCC"},{"key":"R12-20250121","first-page":"1426","article-title":"Src family kinases, new therapeutic targets for intervention of VEGF\u2013mediated retinopathy.","volume":"46","author":"Werdich","year":"2005","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R13-20250121","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1517\/14728222.11.9.1207","article-title":"Regulation of angiogenesis and vascular permeability by Src family kinases: opportunities for therapeutic treatment of solid tumors.","volume":"11","author":"Park","year":"2007","journal-title":"Expert Opin Ther Targets"},{"key":"R14-20250121","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1517\/14740331003742935","article-title":"Pleural\/pericardic effusions during dasatinib treatment: incidence, management and risk factors associated to their development.","volume":"9","author":"Breccia","year":"2010","journal-title":"Expert Opin Drug Saf"},{"key":"R15-20250121","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1182\/blood-2008-09-180604","article-title":"Tyrosine kinase inhibitor-induced platelet dysfunction in patients with chronic myeloid leukemia.","volume":"114","author":"Quint\u00e1s-Cardama","year":"2009","journal-title":"Blood"},{"key":"R16-20250121","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1002\/cncr.24257","article-title":"Bleeding diathesis in patients with chronic myelogenous leukemia receiving dasatinib therapy.","volume":"115","author":"Quint\u00e1s-Cardama","year":"2009","journal-title":"Cancer"},{"key":"R17-20250121","doi-asserted-by":"crossref","first-page":"6697","DOI":"10.1158\/1078-0432.CCR-16-0667","article-title":"Dasatinib reversibly disrupts endothelial vascular integrity by increasing non-muscle myosin II contractility in a ROCK-dependent manner.","volume":"23","author":"Kreutzman","year":"2017","journal-title":"Clin Cancer Res"},{"key":"R18-20250121","doi-asserted-by":"crossref","first-page":"446","DOI":"10.3904\/kjim.2015.325","article-title":"Dasatinib induces severe hemorrhagic colitis in a patient with accelerated phase of chronic myelogenous leukemia.","volume":"33","author":"Yim","year":"2018","journal-title":"Korean J Intern Med"},{"key":"R19-20250121","doi-asserted-by":"crossref","first-page":"1113462","DOI":"10.3389\/fonc.2023.1113462","article-title":"Adverse reactions after treatment with dasatinib in chronic myeloid leukemia: characteristics, potential mechanisms, and clinical management strategies.","volume":"13","author":"Cheng","year":"2023","journal-title":"Front Oncol"},{"key":"R20-20250121","doi-asserted-by":"crossref","first-page":"e231653","DOI":"10.1136\/bcr-2019-231653","article-title":"Chylothorax: complication attributed to dasatinib use.","volume":"12","author":"Al-Abcha","year":"2019","journal-title":"BMJ Case Rep"},{"key":"R21-20250121","doi-asserted-by":"crossref","first-page":"194","DOI":"10.21037\/tcr-22-1983","article-title":"Dasatinib-associated chylothorax in a pediatric patient with chronic myeloid leukemia: a case report and literature review.","volume":"12","author":"Liu","year":"2023","journal-title":"Transl Cancer Res"},{"key":"R22-20250121","doi-asserted-by":"crossref","first-page":"673","DOI":"10.21037\/tp-23-517","article-title":"Dasatinib-induced pleural effusions, pericardial effusion and pulmonary arterial hypertension: a case report.","volume":"13","author":"Zhao","year":"2024","journal-title":"Transl Pediatr"},{"key":"R23-20250121","first-page":"101662","article-title":"Dasatinib-induced massive left chylothorax in a patient with chronic myeloid leukemia.","volume":"37","author":"Makimoto","year":"2022","journal-title":"Respir Med Case Rep"},{"key":"R24-20250121","doi-asserted-by":"crossref","first-page":"e00753","DOI":"10.1002\/rcr2.753","article-title":"Dasatinib-induced chylothorax in a patient with chronic myeloid leukaemia: a case report and literature review.","volume":"9","author":"Hsu","year":"2021","journal-title":"Respirol Case Rep"},{"key":"R25-20250121","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1002\/jha2.226","article-title":"Dasatinib-induced chylothorax: an unusual presentation of a common adverse event \u2013 a case report with literature review.","volume":"2","author":"Paul","year":"2021","journal-title":"EJHaem"},{"key":"R26-20250121","doi-asserted-by":"crossref","first-page":"e938319","DOI":"10.12659\/AJCR.938319","article-title":"Diagnostic pitfalls of chylothorax after dasatinib treatment of chronic myeloid leukemia.","volume":"23","author":"Kelly","year":"2022","journal-title":"Am J Case Rep"},{"key":"R27-20250121","first-page":"71","article-title":"Dasatinib-induced chylothorax in chronic myeloid leukemia.","volume":"30","author":"Baloch","year":"2017","journal-title":"Proc (Bayl Univ Med Cent)"},{"key":"R28-20250121","doi-asserted-by":"crossref","first-page":"e665","DOI":"10.1097\/MPH.0000000000001619","article-title":"Dasatinib-induced chylothorax in chronic myelogenous leukemia in pediatric patient: report of a case and review of literature.","volume":"42","author":"Hickman","year":"2020","journal-title":"J Pediatr Hematol Oncol"},{"key":"R29-20250121","doi-asserted-by":"crossref","first-page":"289","DOI":"10.4103\/1817-1737.191871","article-title":"Dasatinib-induced pleural effusion: chylothorax, an option to consider.","volume":"11","author":"Ferreiro","year":"2016","journal-title":"Ann Thorac Med"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000041328","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T03:03:43Z","timestamp":1737428623000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000041328"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,17]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000041328","relation":{},"ISSN":["1536-5964"],"issn-type":[{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,17]]}}}